Press Releases

Press Releases

Stay updated on the latest VistaGen News and get the details about important events, public financial reports, and our product pipeline updates.

Ann Cunningham has a proven pharmaceutical commercial track record of more than 25 years delivering sales, marketing, and global life cycle product management expertise for many successful branded product campaigns for large pharmaceutical companies SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE
Dr. Curley brings extensive pharmaceutical industry experience in product development, commercialization and operations as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- 
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and
PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and
Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD) Strengthened Balance Sheet upon closing of $100 million underwritten public offering SOUTH SAN
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous
Dr. Louis Monti, VistaGen’s Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review SOUTH SAN FRANCISCO, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) --  VistaGen Therapeutics , Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous